Quick Facts

• Main Therapeutic Domain: Parasitic worm infections
• Conditions Addressed: Ascariasis and hookworm infections
• Other Applications: Used in the management of specific types of cancer, such as colon cancer, as an adjunct to other therapies.

Levasole (Levamisole) is a medication utilized in the treatment of parasitic worm infections. Its principal use is to address infections caused by the roundworm species Ascaris lumbricoides (known as ascariasis) and certain types of hookworm infections, including those caused by Necator americanus and Ancylostoma duodenale.

In some contexts, the medication has also been evaluated for its potential immunomodulatory capabilities. These properties have led to its documented use as an adjuvant treatment in combination with chemotherapy for specific stages of colon cancer. The application of the drug in this context is based on its observed therapeutic effects in these specific clinical situations.

Furthermore, Levasole may be employed to support the management of certain dermatological conditions and has been explored as a treatment option to maintain remission in some pediatric kidney disorders. It is classified as an essential medicine for the treatment of intestinal worm infections.

Eligibility for Levasole Use: Official Regulatory Profile

Levasole (Levamisole) eligibility is defined by regulatory authorities based on a patient's pre-existing conditions and physiological status.

Classification	Population Restriction
Absolute Contraindication	Patients with known hypersensitivity to levamisole or its components
Absolute Contraindication	Patients with a history of serious blood disorders, including agranulocytosis or leukopenia
Absolute Contraindication	Patients with severe, pre-existing hepatic (liver) or renal (kidney) impairment

Age-Related Eligibility:

Levasole is approved for the treatment of parasitic worm infections in both the adult and pediatric populations, with dosing adjusted by body weight for children. Use in older adults is not generally expected to cause different problems than in younger adults. Non-anthelmintic uses (e.g., immunomodulatory) in children are not well-established in official labeling.

Conditional Use and Restrictions:

Use is restricted and requires caution in patients with non-severe hepatic or renal impairment, or with conditions such as epilepsy or certain autoimmune disorders (e.g., rheumatoid arthritis). For pregnancy, Levasole is assigned FDA Pregnancy Category C, meaning it should only be administered if the potential maternal benefit outweighs the potential risk to the fetus. Use during lactation is generally not recommended due to insufficient data on infant risk.

Interactions with other medicines and products

Official regulatory documents define specific drug-drug and drug-product interactions for Levasole (Levamisole) that necessitate restrictions on co-administration.

---

Formal Restrictions and Contraindications

Co-administration with organophosphorus compounds is a formal contraindication due to the risk of enhanced toxicity. Regulatory guidance specifies that treatment with Levamisole must be separated by a minimum of 14 days from the use of these compounds. The combination of Levamisole with alcohol (Ethanol) is also restricted, as it may result in a severe disulfiram-like reaction.

Documented Exposure-Altering Interactions

Levamisole has been documented to affect the clearance and exposure of several co-administered medicines. It may increase the effects or toxicity of certain drugs, including Warfarin (an anticoagulant) and Phenytoin (an antiepileptic), potentially necessitating monitoring procedures. Furthermore, Levamisole can affect the systemic availability of other anthelmintics: it is documented to decrease the bioavailability of Albendazole while increasing the bioavailability of Ivermectin.

Population and Procedural Constraints

Official prescribing information advises caution for use in patients with liver disease due to the risk of altered drug clearance. Additionally, when used in combination with Fluorouracil, official documentation requires the monitoring of liver function tests for potential hepatotoxicity.

Anthelmintic Action: Inducing Spastic Paralysis

The mechanism underlying the effect on nematodes is the agonism (activation) of nicotinic acetylcholine receptors (nAChRs) specifically located on the somatic muscle cells of the parasite. This interaction triggers a persistent influx of calcium ions, resulting in the sustained depolarization and spastic paralysis of the worm's musculature, leading to its immobilization.

---

Immunomodulation: Normalizing Depressed T-Cell Function

The drug possesses a unique secondary mechanism by modulating the function of the host's cellular immune system, primarily impacting T-lymphocytes and macrophages. Levamisole modulates the immune system's function, meaning its effect is the normalization of cellular function when activity is compromised. This includes boosting the cells' phagocytic activity and normalizing cytokine release, modulating T-cell and macrophage activity.

How Levasole is Used: Administration Guidelines

Levasole (levamisole) is an oral medication with two distinct dosing protocols: a single-dose regimen for parasitic infections and a cyclical schedule for its historical use as an adjuvant therapy in certain cancers. Administration is guided by the information provided in the prescribing documentation.

Dosing and Schedule Structure

The usage of Levasole is structured by the medical context, which dictates the dose, frequency, and duration.

Usage Context	Standard Adult Dose & Schedule	Population-Specific Rules
Parasitic Infections	150 mg taken as a single oral dose.	Children: Dose is weight-based at 2.5 mg/kg body weight as a single oral dose.
Adjuvant Cancer Therapy	50 mg taken orally every 8 hours for 3 days, repeated every 2 weeks.	Combination Therapy: The dose of the co-administered drug (Fluorouracil) is adjusted, deferred, or reduced based on blood cell counts (WBC/Platelets).

---

Administration Conditions and Duration

• Route of Administration: Levasole is administered via the oral route only, typically supplied as tablets or an oral solution.
• Timing in Relation to Meals: The medication may be taken with or without food.
• Treatment Duration: The anthelmintic use is generally a one-time administration. The adjuvant cancer therapy protocol involves repeating the 3-day course at two-week intervals for a total duration of 1 year.
• Procedural Requirement: When used as an adjuvant therapy, the first 3-day course is scheduled to be initiated 7 to 30 days following surgery to align with the treatment protocol.

Research Evidence / Overview of Studies for Levasole

Evidence for Use in Parasitic Worm Infections

Research examining studies for parasitic worm infections, chiefly Ascariasis, has involved short-term randomized controlled trials (RCTs) monitoring the Parasitological Cure Rate (PCR). Studies focusing on Ascaris lumbricoides reported high measurements of PCR. However, findings for hookworm species were more variable, and research describes that certain parasitic worms, such as whipworm, showed low measurements of response. Uncertainty remains regarding the need for extensive long-term follow-up to fully characterize the risk of reinfection beyond the typical 60-day study period.

---

Evidence for Use as Adjuvant Treatment for Colon Cancer

Levamisole was evaluated in large, long-term, multi-center RCTs as an adjuvant treatment for Stage III colon cancer. Studies monitored Overall Survival (OS) and Disease-Free Survival (DFS). Pivotal research describes that long-term measurements related to three-year and five-year survival were reported in studies that evaluated the combination with 5-Fluorouracil. Research exploring high-dose regimens reported different findings. The data are historical, and comparative evidence against current standards of care is lacking.

---

Evidence for Use in Pediatric Nephrotic Syndrome

Research has explored Levamisole in studies evaluating how it relates to the use of steroids in children with frequently relapsing (FRNS) or steroid-dependent (SDNS) nephrotic syndrome. Studies monitored relapse outcomes and cumulative steroid dose over 6- to 12-month intervals. Patient groups receiving the drug had measured patterns of relapse frequency that differed from control groups. However, certainty remains low in some areas because sample sizes were modest, and data regarding the durability of effects after treatment cessation are not fully established.

---

Long-Term Studies and Follow-up

Follow-up duration varies significantly, ranging from 14 to 60 days for parasitic infections to five years for colon cancer studies. Data for certain groups remain insufficient for determining the long-term pattern of symptom evolution across all indications.

What Is Still Uncertain About Levasole

Key limitations noted include modest sample sizes in some clinical trials and varying quality of evidence when comparing the drug to other medicines studied in the same context. Research primarily focused on specific age groups and disease stages, and limited information is available for other specific populations, such as older adults or those with multiple comorbidities.

Key Studies & References

1. WHO Model List of Essential Medicines (Relevant Anthelminthic listing)

Common questions about Levasole (FAQ)

---

Q: How quickly does Levasole start to show noticeable effects?

According to official product information, Levasole is absorbed rapidly after taking an oral dose. The concentration of the medicine in the blood reaches its peak in about 1.5 to 2 hours. This indicates that the medicine is quickly available in the body to begin its intended action.

---

Q: Can Levasole cause dizziness or affect driving?

Official safety documents indicate that Levamisole can cause effects on the nervous system, such as dizziness and sleepiness. Official labeling advises caution with tasks requiring mental alertness, such as driving or operating machinery, if symptoms like dizziness or sleepiness occur.

---

Q: Is it normal to feel a bit nauseous after starting Levasole?

Yes, nausea is listed as one of the most common adverse reactions reported in clinical data for Levasole. Other gastrointestinal disturbances, including vomiting and abdominal pain, are also frequently reported. If nausea is severe or does not go away, contact your prescribing healthcare professional for guidance.

---

Q: How long does Levasole stay in your system after stopping the medication?

Levasole is cleared from the body relatively quickly. The half-life—the time it takes for half of the drug to be eliminated from the plasma—is approximately 3 to 4 hours. However, the elimination of the breakdown products (metabolites) is longer, and the drug is predominantly excreted via the kidneys over the course of three days.

---

Q: Are there special considerations for people with kidney issues when taking Levasole?

Official regulatory warnings advise that Levamisole should be used with caution if there is a history of kidney disease. Severe kidney impairment is listed as an absolute contraindication. The restriction is noted because the drug's elimination involves the kidneys.

---

Q: Does Levasole show up on standard drug tests?

Levamisole and its metabolites (chemical breakdown products) can be detected and quantified in biological samples, such as urine and blood, using specialized laboratory techniques. These tests allow for the detection and measurement of Levamisole.

---

Q: Is there a generic version of Levasole available?

Yes, the active ingredient in Levasole is Levamisole. Regulatory databases, such as the FDA's approved drug products list, confirm that generic versions of Levamisole hydrochloride products have been approved and marketed.

---

Q: What if I'm taking other prescription medications with Levasole?

Levasole has documented interactions with specific medications, including the anticoagulant Warfarin and the antiepileptic Phenytoin. The combination of Levamisole with alcohol and certain organophosphorus compounds is also restricted. It is important for a healthcare professional to review all medications being taken.

---

Q: How common is an allergic reaction to Levasole?

Official safety data lists skin rash and itching (pruritus) as uncommon side effects. Hypersensitivity (allergic reaction) is listed as an absolute contraindication, meaning the drug should not be used if a patient has a known allergy to its components.

---

Q: Can Levasole cause changes in sleep patterns?

Official reports classify insomnia (sleeplessness) as an uncommon psychiatric side effect of Levamisole. If you notice changes in your sleep patterns, consult with a healthcare professional.

---

Q: Is it better to take Levasole in the morning or at night?

Official regulatory information does not specify a preferred time of day for taking Levasole. The drug is approved to be administered orally and can be taken with or without food. This approach allows the timing of the dose to be determined based on the prescribing professional’s instructions.

---

Q: Can Levasole cause long-term side effects?

Regulatory safety information indicates that the risk of the most serious blood disorders and nervous system toxicities is reported primarily in association with repeated or prolonged dosing regimens. These risks are notably higher when the drug is used for long-term immunomodulatory therapy, compared to the single-dose antiparasitic treatment.

---

Q: Is Levasole known by any other brand names internationally?

Yes, the active ingredient Levamisole is marketed under several different brand names in various countries. Some of these trade names include Decaris, Ergamisol, Ketrax, and Solaskil.

Storage and Disposal Requirements for Levasole

Official labeling mandates specific conditions for storing and disposing of Levasole to maintain its stability and effectiveness.

Storage Conditions

The product must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is required to keep the product from freezing and to protect it from light. The medicine must be kept in its original container and the container must remain tightly closed.

As a mandatory safety requirement, Levasole must be stored out of the sight and reach of children.

Handling and Disposal

For stability, specific prepared solutions (from powder formulations) may be stored for up to 90 days. Unused or expired Levasole must be disposed of in accordance with local or regional regulations, often requiring disposal via an approved waste disposal plant. The product must not be poured into wastewater or disposed of in the household trash, unless specifically authorized by official labeling.